Century Therapeutics (IPSC) Price & Analysis

Compare

212 Followers

IPSC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.34 - $1.83

Previous CloseN/A

Volume712.78K

Average Volume (3M)545.74K

Market Cap

$48.26M

Enterprise Value-$56.18M

Total Cash (Recent Filing)$155.84M

Total Debt (Recent Filing)$51.48M

Price to Earnings (P/E)―

Beta2.00

Next Earnings

Nov 06, 2025

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.38

Shares Outstanding86,389,100

10 Day Avg. Volume678,722

30 Day Avg. Volume545,736

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-1.16

Enterprise Value/Revenue-0.49

Enterprise Value/Gross Profit-0.51

Enterprise Value/Ebitda4.33

Forecast

1Y Price Target

$4.50

Price Target Upside675.86% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Financial PerformanceThe company's cash runway has been extended into the fourth quarter of 2027, providing financial stability for future operations.

Pipeline ExpansionThe ongoing IND-enabling studies for CNTY-308 and plans to advance it into the clinic in 2026 show a commitment to expanding the therapeutic pipeline.

Product DevelopmentCNTY-101 is seen as a differentiated product for autoimmune disease given its strong safety profile and potentially reduced lymphodepletion requirements.

Bears Say

Clinical TrialsEnrollment in the CALiPSO-1 trial is still lagging, with only two patients dosed as of 2Q.

Data InterpretationThere are confounders that could reduce the interpretability of the first readout including diverse AID indications and geographic diversity.

Regulatory RisksRisks include the inability to secure regulatory approval for investigational therapies, notably CNTY-101.

Century Therapeutics News

Century Therapeutics Granted Nasdaq Compliance Extension

An update from Century Therapeutics ( ($IPSC) ) is now available. On February 26, 2025, Century Therapeutics received...

1M ago

IPSC

Century Therapeutics Reports Q2 2025 Financials and Updates

Century Therapeutics, Inc. ( ($IPSC) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

IPSC

Century Therapeutics: Strategic Workforce Reduction and Financial Position Justify Hold Rating Amid Developmental Progress and Challenges

William Blair analyst Sami Corwin has maintained their neutral stance on IPSC stock, giving a Hold rating on...

2M ago

IPSC

Century Therapeutics Reports Q2 Results and Leadership Change

Century Therapeutics ( ($IPSC) ) has issued an announcement. On August 14, 2025, Century Therapeutics announced its second...

2M ago

IPSC

Century Therapeutics files $200M mixed securities shelf

16:51 EDT Century Therapeutics (IPSC) files $200M mixed securities shelf Published first on TheFly – the ultimate source...

3M ago

IPSC

Century Therapeutics Announces Major Workforce Reduction

An announcement from Century Therapeutics ( ($IPSC) ) is now available. On July 1, 2025, Century Therapeutics‘ Board...

3M ago

IPSC

Century Therapeutics Holds 2025 Annual Stockholders Meeting

Century Therapeutics ( ($IPSC) ) just unveiled an update. On June 12, 2025, Century Therapeutics, Inc. conducted its...

4M ago

IPSC

Century Therapeutics Reports Strong Q1 2025 Earnings

Century Therapeutics, Inc. ( ($IPSC) ) has released its Q1 earnings. Here is a breakdown of the information...

5M ago

IPSC

Century Therapeutics Reports Strong Q1 2025 Financial Results

An announcement from Century Therapeutics ( ($IPSC) ) is now available. On May 15, 2025, Century Therapeutics reported...

5M ago

IPSC

Century Therapeutics: Strategic Advancements and Promising Preclinical Data Justify Buy Rating

Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Century Therapeutics (IPSC – Research Report), retaining...

6M ago

IPSC

Century Therapeutics price target lowered to $2 from $5 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Century Therapeutics (IPSC) to $2 from $5 and keeps a...

6M ago

IPSC

Century Therapeutics price target lowered to $7 from $11 at Chardan

Chardan lowered the firm’s price target on Century Therapeutics (IPSC) to $7 from $11 and keeps a Buy...

7M ago

IPSC

Century Therapeutics price target lowered to $5 from $12 at Guggenheim

Guggenheim analyst Kelsey Goodwin lowered the firm’s price target on Century Therapeutics (IPSC) to $5 from $12 and...

7M ago

IPSC

Century Therapeutics Reports 2024 Financial Results and Strategic Updates

Century Therapeutics, Inc. ( ($IPSC) ) has released its Q4 earnings. Here is a breakdown of the information...

7M ago

IPSC

IPSC FAQ

What was Century Therapeutics’s price range in the past 12 months?

Century Therapeutics lowest stock price was $0.34 and its highest was $1.83 in the past 12 months.

What is Century Therapeutics’s market cap?

Century Therapeutics’s market cap is $48.26M.

When is Century Therapeutics’s upcoming earnings report date?

Century Therapeutics’s upcoming earnings report date is Nov 06, 2025 which is in 28 days.

How were Century Therapeutics’s earnings last quarter?

Century Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.376 by -$0.004.

Is Century Therapeutics overvalued?

According to Wall Street analysts Century Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Century Therapeutics pay dividends?

Century Therapeutics does not currently pay dividends.

What is Century Therapeutics’s EPS estimate?

Century Therapeutics’s EPS estimate is -0.34.

How many shares outstanding does Century Therapeutics have?

Century Therapeutics has 86,389,100 shares outstanding.

What happened to Century Therapeutics’s price movement after its last earnings report?

Century Therapeutics reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.376. Following the earnings report the stock price went up 1.818%.

Which hedge fund is a major shareholder of Century Therapeutics?

Currently, no hedge funds are holding shares in IPSC

Century Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-10.78%

Trailing 12-Months

Asset Growth

-31.64%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Century Therapeutics

Century Therapeutics is a biotechnology company focused on developing and commercializing innovative cell therapies for the treatment of cancer. Utilizing its proprietary induced pluripotent stem cell (iPSC) technology, Century aims to create off-the-shelf, genetically engineered immune cell therapies that can be tailored for multiple cancer types. The company operates within the sectors of regenerative medicine and oncology, with core products centered around its iPSC-derived cell therapies designed to enhance the efficacy and accessibility of cancer treatments.

Century Therapeutics (IPSC) Earnings & Revenues

Historic Earnings Reports

IPSC Stock 12 Month Forecast

Average Price Target

$4.50

▲(675.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,1,1.5,2,2.5,3,3.5,4,4.5,5,5.5,6,6.5,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,0.8076923076923077,1.1153846153846154,1.4230769230769231,1.7307692307692308,2.0384615384615383,2.3461538461538463,2.653846153846154,2.9615384615384617,3.269230769230769,3.576923076923077,3.884615384615385,4.1923076923076925,{"y":4.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.5,0.6153846153846154,0.7307692307692308,0.8461538461538461,0.9615384615384616,1.076923076923077,1.1923076923076923,1.3076923076923077,1.4230769230769231,1.5384615384615385,1.653846153846154,1.7692307692307694,1.8846153846153846,{"y":2,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.09,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.68,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.01,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.54,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.53,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >